Was 2013 als Start-up mit einem Gründerteam von fünf Schlüsselpersonen begann, hat sich zu einem Pharmaunternehmen mit eigener GMP-zertifizierter Nanofactory und über 50 Mitarbeitenden entwickelt. Mit einem erfahrenen Verwaltungsrat und der eingespielten Geschäftsleitung vereint InnoMedica umfangreiches Know-how, um die anstehenden Projekte erfolgreich zu realize.
Today, the InnoMedica team consists of over 50 employees. InnoMedica's strong technical focus is reflected in the large number of employees with degrees in biochemistry, chemistry, biomedicine or pharmacy. The high level of expertise in this core area is an important factor in InnoMedica's success.
When recruiting, InnoMedica places a strong emphasis on the motivation and interests of its employees. Great importance is placed on employee participation with regard to their personal development within the company in order to fully develop their potential and enable internal promotion.
The Board of Directors of InnoMedica Holding AG, headed by Dr. Peter Halbherr as Chairman, ensures quick decisions and direct action. Thanks to the biochemical background of Dr. Noboru Yamazaki, the medical knowledge of Dr. med. Denis Bron and the economic and entrepreneurial expertise of Prof. Dr. Urs Wälchli, the Board of Directors can rely on know-how from various areas. The active involvement of the members of the Board of Directors in individual projects ensures proximity to InnoMedica's operational activities. This is essential in order to take account of the dynamic nature of the company.
With the founding team of Dr. Stéfan Halbherr, Andrea Zurkirchen, Dr. Jonas Zeller and Pascal Halbherr on the management board of InnoMedica Schweiz AG, the company benefits from an experienced and well-coordinated team for the efficient management of the company. In 2022, Dr. Camille Peitsch and in 2023 Dr. Martin Stähle joined the management board. As Country Manager of InnoMedica Schweiz AG, Dr. Stéfan Halbherr takes over the management of the operational business. Andrea Zurkirchen is responsible for Communications, HR and Legal & Compliance, while Dr. Jonas Zeller is in charge of Business Development. Pascal Halbherr is Head of Manufacturing and is therefore responsible for the operational processes at the Nanofactory in Marly. Dr. Camille Peitsch is responsible for Research, Development and Sales and Dr. Martin Stähle for Finance and Administration.
Dr. phil. et phil., Universities of Zurich and Paris
Chairman of the board, Delegate and General Manager
Dr. med., University of Basel
Member of the board, Vice-Chairman
Dr. rer. oec., University of Bern
Member of the board
Dr. rer. nat.
Member of the board, Chief Technology Officer
PhD, University of Bern
Leiter Forschung & Entwicklung, InnoMedica Holding und Country Manager, InnoMedica Schweiz
Leiter Finanzen & Administration, InnoMedica Holding, Leiter Business Development, InnoMedica Schweiz
lic. phil., University of Zurich
Stab, Investor Relation & Legal, InnoMedica Holding und Leiterin Management Services, InnoMedica Schweiz
MSc Biochemistry, University of Bern
Head Manufacturing; InnoMedica Switzerland
Leiterin Forschung, Entwicklung & Verkauf, InnoMedica Schweiz
Dr. oec., University of Hohenheim
Leiter Finanzen & Administration, InnoMedica Schweiz
